Amgen is quickly approaching resistance at its recent high of $446.05, with an SIA SMAX Score of 10/10 and substantial gains in relative positioning. The shares rank 42 in the SIA S&P 500 Index Report, having climbed 55 positions over the past month and 131 over the past quarter.
The latest Point & Figure signal is a Double Top. The recent high remains the immediate technical hurdle, with further resistance at the psychological round number of $500.00. On the downside, support stands at the 3-box reversal level of $396.08, followed by $373.23.
The Drugs sector provides a strong relative-strength backdrop. It is classified as Favored in the SIA Sector Report and ranks 2 out of 31 sectors, up one position over the past quarter. Amgen’s improvement in stock ranking therefore accompanies an already highly ranked sector.
Amgen has outperformed the iShares Core S&P 500 ETF Fund (IVV) across all three reported periods. The shares gained 10.19% monthly, 16.67% quarterly and 32.49% year to date, compared with benchmark advances of 0.67%, 3.42% and 13.69%, respectively. That outperformance complements the rise in report ranking, while the approaching resistance level leaves the next price hurdle unresolved. These technical strengths sit within the broader assessment of portfolio objectives and risk exposure.
Amgen discovers, develops, manufactures and delivers medicines for conditions including cancer, inflammatory diseases, rare diseases, heart disease, obesity and obesity-related conditions. Headquartered in Thousand Oaks, California, the company helped establish the biotechnology industry more than 45 years ago and uses biological research, technology and human genetic data in medicine development.
Disclaimer: SIACharts Inc. specifically represents that it does not give investment advice or advocate the purchase or sale of any security or investment whatsoever. This information has been prepared without regard to any particular investors investment objectives, financial situation, and needs. None of the information contained in this document constitutes an offer to sell or the solicitation of an offer to buy any security or other investment or an offer to provide investment services of any kind. As such, advisors and their clients should not act on any recommendation (express or implied) or information in this report without obtaining specific advice in relation to their accounts and should not rely on information herein as the primary basis for their investment decisions. Information contained herein is based on data obtained from recognized statistical services, issuer reports or communications, or other sources, believed to be reliable. SIACharts Inc. nor its third party content providers make any representations or warranties or take any responsibility as to the accuracy or completeness of any recommendation or information contained herein and shall not be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon. Any statements nonfactual in nature constitute only current opinions, which are subject to change without notice.
